BD Rx Inc., a subsidiary of global MedTech company
Becton, Dickinson and Company
), has won the U.S. Food and Drug Administration (FDA) approval
for Ondansetron Injection, USP 4mg/2mL (2mg/mL). It is the third
drug to be launched in the BD Simplist line of prefilled generic
ALIGN TECH INC (ALGN): Free Stock Analysis
BECTON DICKINSO (BDX): Free Stock Analysis
COOPER COS (COO): Free Stock Analysis Report
MCKESSON CORP (MCK): Free Stock Analysis
To read this article on Zacks.com click here.
Deemed as the future of all injectables, the BD Simplist
prefilled injectables are uniquely designed so as to reduce the
number of steps in the traditional vial-and-syringe injection
sequence from 20 to 12 steps. This lowers the possible risk of
medication error, and at the same time, enhances patient safety
and clinical outcome.
The Ondansetron Injection, USP, an injectable antiemetic, is used
to stop nausea and vomiting, post surgeries. It also has
applications in emetogenic cancer chemotherapy. Moreover, the
drug is on the FDA shortage list owing to supply scarcity in the
U.S. This is clearly indicative of the considerable
opportunity that the drug holds of capturing a significant share
in the domestic market.
The FDA approval along with the huge demand in the underlying
market is expected to boost the company's sluggish U.S. business.
Domestic revenues (contributing 41.3% to total revenues) inched
up 1.3% year over year to $848 million in the last reported
The BD Rx business is an extension of the BDX's pharmaceutical
offerings, a leader in glass prefillable syringe manufacturing.
The two other drugs that are already available in the market from
the BD Simplist product line include the Metoclopramide
Injection, USP and Diphenhydramine Hydrochloride Injection,
USP. Given the huge demand for acute care generic
injectables, the BD Rx division plans to roll out 20 to 30 more
drugs from its BD Simplist line of products within the next few
BDX has a Zacks Rank #3 (Hold). While we remain on the sidelines
regarding Becton, Dickinson and Company, other medical stocks
worth considering include
The Cooper Companies
). All these stocks carry a Zacks Rank #2 (Buy).